Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Agiolax + phenolphthalein is a combination laxative that integrates bulk-forming, stimulant, and contact laxative properties. The Agiolax component typically consists of *Plantago ovata* (psyllium) seeds and husks, which act as bulk-forming agents by absorbing water and increasing stool volume, and *Senna* (containing sennosides), which stimulates colonic peristalsis. Phenolphthalein is a potent stimulant laxative that acts directly on the intestinal mucosa to increase motor activity and inhibit water absorption. While Agiolax remains a widely used herbal laxative, the addition of phenolphthalein was common in older formulations before phenolphthalein was largely phased out in many jurisdictions due to concerns regarding its potential carcinogenicity. The combination was primarily indicated for the short-term treatment of acute or chronic constipation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on psyllium + senna + phenolphthalein.